VALNEVA
LIVE

Serial Number

79138125

Owner

VALNEVA

Attorney

Christina M. Licursi

Filing Date

May 31, 2013

Add to watchlist:

No watchlists yet
View on USPTO

VALNEVA Trademark

Serial Number: 79138125 • Registration: 4686292

VALNEVA is a trademark filed by VALNEVA on May 31, 2013. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

VALNEVA (5 trademarks)

6 rue Alain Bombard

Entity Type: 99

Trademark Details

Filing Date

May 31, 2013

Registration Date

February 17, 2015

Published for Opposition

December 2, 2014

Goods & Services

Pharmaceuticals for human and veterinary use for the treatment of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; antibodies and fragments thereof for use in disease testing; cell cultures, microorganisms and viruses for medical and veterinary use; diagnostic agents for medical, pharmaceutical and veterinary use; cells for medical or clinical use; culture media for cultivating microorganism cells for medical and veterinary use; adjuvants for medical or and veterinary use; pharmaceutical and veterinary preparations for medical, pharmaceutical and veterinary use, namely, preparations of encapsulated cells which release antibodies, living cells and microorganisms, vaccines, viral vectors, proteins, peptides, enzymes, nucleic acids or pharmaceutically active compounds for the treatment of cancer, auto-immune disorders, infectious diseases, inflammatory diseases, neurological and genetic disorders, bowel diseases, and digestion problems

Chemicals for use in industry, science and agriculture, except fungicides, herbicides, insecticides and parasiticides; molecules from biotechnologies, namely, proteins in raw material for industrial use, scientific or medical research; cells and cell lines for use in scientific, laboratory, or medical research; nucleic acids for laboratory use; proteins in raw material form for scientific and medical research; recombinant proteins in raw material form for scientific and medical research; Biomedical compounds, namely, peptide substrates and peptide antigens used in analyzing and detecting certain toxins for clinical or medical laboratory use; Biochemical preparations derived from blood serum used as growth promoters in tissue cultures and microbiological media; Biochemicals, namely, antibodies and fragments thereof for in vitro scientific or research use; Chemicals for use in biotechnological product development; Cultures of microorganisms other than for medical and veterinary use; Biological preparations and bacteriological preparations for use in cell cultures other than for medical or veterinary use

Scientific research services for medical purposes in the fields of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; scientific research for medical, pharmaceutical and veterinary purposes in the fields of autoimmune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; scientific research, in particular, in the fields of biology, cellular and molecular biology, biotechnology, bacteriology, immunology, genetics, medicine, pharmacology, virology, chemistry; scientific research relating to vaccines, antibiotics and immunological products for human and veterinary use; research and development of new products for others; testing, analysis, and evaluation of the goods of others to assure compliance with industry standards in the scientific, medical and veterinary fields; development and design of laboratory instruments for scientific and industrial research, in particular, to obtain and prepare cells, cell lines, viruses, proteins, animal and human materials; development of vaccines, antibiotics and immunological products for human and veterinary use; scientific and technological services, namely, diagnostic and prognostic analyses in the fields of cells, cell lines, animal and human materials, microorganisms, molecules for scientific purposes; scientific research, namely, preparation of scientific experts opinions reports

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
May 9, 2025 NA71
REGISTERED-SEC.71 ACCEPTED
May 9, 2025 71AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 5, 2025 APRE
TEAS SECTION 71 RECEIVED
Dec 27, 2024 ES71
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
May 22, 2024 LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Apr 25, 2024 LIMN
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Feb 25, 2024 RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Feb 17, 2024 RHRD
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Feb 17, 2024 REM4
INTERNATIONAL REGISTRATION RENEWED
Apr 7, 2023 RNWL
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Nov 3, 2022 LIMN
NEW REPRESENTATIVE AT IB RECEIVED
Oct 15, 2022 NREP
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
Oct 1, 2022 RHRD
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Nov 30, 2020 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Nov 30, 2020 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 24, 2020 APRE
TEAS SECTION 71 & 15 RECEIVED
Jul 8, 2020 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 17, 2020 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Sep 26, 2019 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 13, 2018 ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 22, 2016 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 31, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 29, 2015 FICS
FINAL DISPOSITION PROCESSED
Jun 29, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 17, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 17, 2015 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 2, 2014 NPUB
PUBLISHED FOR OPPOSITION
Dec 2, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 12, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 29, 2014 PREV
ASSIGNED TO LIE
Oct 28, 2014 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 9, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 9, 2014 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 9, 2014 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 9, 2014 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 9, 2014 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 24, 2014 GNFN
FINAL REFUSAL E-MAILED
Apr 24, 2014 GNFR
FINAL REFUSAL WRITTEN
Apr 24, 2014 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 9, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 9, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 9, 2014 TROA
REFUSAL PROCESSED BY IB
Dec 10, 2013 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 20, 2013 RFCS
REFUSAL PROCESSED BY MPU
Nov 20, 2013 RFRR
APPLICATION FILING RECEIPT MAILED
Nov 19, 2013 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 16, 2013 RFCR
NON-FINAL ACTION WRITTEN
Nov 15, 2013 CNRT
ASSIGNED TO EXAMINER
Nov 13, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 13, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 11, 2013 REPR